This is my talk from the 14th Annual Portfolio Planning and Partnership for Generic Conference. I discuss: Identifying generic entry […]
Generic Portfolio Management, Partnering with Brands, and Staying Competitive Read Post »
We prefer simple flat-rate unrestricted subscriptions — we’ll work on your terms, and with your favorite subscription contract template, to find
Thinking of signing your company up for DrugPatentWatch? Read Post »
Here is a copy of the talk I gave at the recent Marcusevans 13th Portfolio Management and Pipeline Optimization for
Finding and Evaluating Generic Drug Market Entry Opportunities Read Post »
Don’t wait until the end of the year to start looking for alternatives to your existing business intelligence providers. DrugPatentWatch
Let DrugPatentWatch build custom dashboards and reports to take the load off of your team. We can ensure the production
DrugPatentWatch serves companies across the drug development-delivery sector. A common request among drug manufacturers, payers, and suppliers alike is anticipation
Customer Success: Will a generic version of a drug launch? And when? Read Post »
DrugPatentWatch can help identify generic entrants at the earliest stages Many clients come to DrugPatentWatch seeking to identify generic entrants
Customer Success: How do we identify generic entrants before they get FDA approval? Read Post »
Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.
Loss of exclusivity doesn’t mean the end of the income stream for branded drugs. Here’s how drug companies can mitigate the effects of drug patent expiration.
6 Ways to Maximize Product Value as Loss of Exclusivity Approaches Read Post »
Get fresh news and insights, drug patent expirations & more…
